{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:25:14Z","timestamp":1761582314930,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s11096-023-01662-1","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T12:02:30Z","timestamp":1700654550000},"page":"158-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3583-9518","authenticated-orcid":false,"given":"Wenwang","family":"Lang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"issue":"1","key":"1662_CR1","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12876-022-02361-3","volume":"22","author":"D Pan","year":"2022","unstructured":"Pan D, Wang M, Liu W, et al. Clinical-pathological characteristics and prognostic factors for malignant peritoneal mesothelioma in the elderly. BMC Gastroenterol. 2022;22(1):292.","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"1662_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.00953-2019","volume":"55","author":"A Scherpereel","year":"2020","unstructured":"Scherpereel A, Opitz I, Berghmans T, et al. ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1.","journal-title":"Eur Respir J"},{"key":"1662_CR3","doi-asserted-by":"publisher","first-page":"2782590","DOI":"10.1155\/2017\/2782590","volume":"2017","author":"R Shavelle","year":"2017","unstructured":"Shavelle R, Vavra-Musser K, Lee J, et al. Life expectancy in pleural and peritoneal mesothelioma. Lung Cancer Int. 2017;2017:2782590.","journal-title":"Lung Cancer Int"},{"issue":"5","key":"1662_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488\u201399.","journal-title":"Ann Oncol"},{"key":"1662_CR5","doi-asserted-by":"publisher","first-page":"1204722","DOI":"10.3389\/fonc.2023.1204722","volume":"13","author":"RK Sahu","year":"2023","unstructured":"Sahu RK, Ruhi S, Jeppu AK, et al. Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies. Front Oncol. 2023;13:1204722.","journal-title":"Front Oncol"},{"issue":"7","key":"1662_CR6","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","volume":"9","author":"AS Mansfield","year":"2014","unstructured":"Mansfield AS, Roden AC, Peikert T, et al. B7\u2013H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014;9(7):1036\u201340.","journal-title":"J Thorac Oncol"},{"key":"1662_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","volume":"87","author":"DB Chapel","year":"2019","unstructured":"Chapel DB, Stewart R, Furtado LV, et al. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28\u20138 pharmDx assays. Hum Pathol. 2019;87:11\u20137.","journal-title":"Hum Pathol"},{"issue":"18","key":"1662_CR8","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","volume":"25","author":"M Okada","year":"2019","unstructured":"Okada M, Kijima T, Aoe K, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). Clin Cancer Res. 2019;25(18):5485\u201392.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1662_CR9","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","volume":"13","author":"J Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13(10):1569\u201376.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1662_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239\u201353.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1662_CR11","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","volume":"22","author":"DA Fennell","year":"2021","unstructured":"Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22(11):1530\u201340.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1662_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139.","journal-title":"Value Health"},{"issue":"3","key":"1662_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O","volume":"9","author":"CJ Murray","year":"2000","unstructured":"Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235\u201351.","journal-title":"Health Econ"},{"key":"1662_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens M, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:13.","journal-title":"BMC Med Res Methodol"},{"key":"1662_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.619376","volume":"11","author":"W Li","year":"2021","unstructured":"Li W, Guo H, Li L, et al. Comprehensive comparison between adjuvant targeted therapy and chemotherapy for EGFR-mutant NSCLC patients: a cost-effectiveness analysis. Front Oncol. 2021;11: 619376.","journal-title":"Front Oncol"},{"key":"1662_CR16","doi-asserted-by":"publisher","first-page":"8219","DOI":"10.2147\/CMAR.S335515","volume":"13","author":"YT Lin","year":"2021","unstructured":"Lin YT, Chen Y, Liu TX, et al. Cost-effectiveness analysis of camrelizumab immunotherapy versus docetaxel or irinotecan chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma. Cancer Manag Res. 2021;13:8219\u201330.","journal-title":"Cancer Manag Res"},{"key":"1662_CR17","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1186\/1471-2407-14-984","volume":"14","author":"B Wu","year":"2014","unstructured":"Wu B, Li T, Cai J, et al. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer. 2014;14:984.","journal-title":"BMC Cancer"},{"key":"1662_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110543","volume":"122","author":"Y Shu","year":"2023","unstructured":"Shu Y, Tang Y, Ding Y, et al. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma. Int Immunopharmacol. 2023;122: 110543.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"1662_CR19","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/liv.14795","volume":"41","author":"F Wen","year":"2021","unstructured":"Wen F, Zheng H, Zhang P, et al. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis in China and the United states. Liver Int. 2021;41(5):1097\u2013104.","journal-title":"Liver Int"},{"key":"1662_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.906956","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Liang X, Li H, et al. Nivolumab versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: a cost-effectiveness analysis. Front Pharmacol. 2022;13: 906956.","journal-title":"Front Pharmacol"},{"key":"1662_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2022.03.012","volume":"167","author":"A Scherpereel","year":"2022","unstructured":"Scherpereel A, Antonia S, Bautista Y, et al. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer. 2022;167:8\u201316.","journal-title":"Lung Cancer"},{"key":"1662_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.05.012","volume":"110","author":"M Zhan","year":"2017","unstructured":"Zhan M, Zheng H, Xu T, et al. Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial. Lung Cancer. 2017;110:1\u20136.","journal-title":"Lung Cancer"},{"key":"1662_CR23","doi-asserted-by":"publisher","first-page":"175883592211166","DOI":"10.1177\/17588359221116604","volume":"14","author":"L Yang","year":"2022","unstructured":"Yang L, Cao X, Li N, et al. Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma. Ther Adv Med Oncol. 2022;14:17588359221116604.","journal-title":"Ther Adv Med Oncol"},{"key":"1662_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.947375","volume":"10","author":"ZM Ye","year":"2022","unstructured":"Ye ZM, Tang ZQ, Xu Z, et al. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma. Front Public Health. 2022;10: 947375.","journal-title":"Front Public Health"},{"issue":"3","key":"1662_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s11096-023-01540-w","volume":"45","author":"K Xu","year":"2023","unstructured":"Xu K, Wu H, Zhou C, et al. Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma. Int J Clin Pharm. 2023;45(3):641\u20139.","journal-title":"Int J Clin Pharm"},{"key":"1662_CR26","doi-asserted-by":"publisher","first-page":"1044678","DOI":"10.3389\/fimmu.2022.1044678","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Liu K, Qin Q, et al. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis. Front Immunol. 2022;13:1044678.","journal-title":"Front Immunol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01662-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-023-01662-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01662-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T10:25:33Z","timestamp":1706696733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-023-01662-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1662"],"URL":"https:\/\/doi.org\/10.1007\/s11096-023-01662-1","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"assertion":[{"value":"14 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}